Progesterone receptor nuclear morphology patterns in breast cancer.

Slides:

Advertisements

Similar presentations

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

Advertisements

Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Flow chart of the used methodology adapted from Moher et al

The decision tree with the two alternatives.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Detection rate for EGFR mutations in cfDNA.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

Histological and molecular heterogeneity of triple negative breast cancer (TNBC). Histological and molecular heterogeneity of triple negative breast cancer (TNBC).

Methods distribution among the three EQAs

Changes in haemoglobin over the course of the treatment in a patient with chronic myeloid leukaemia who developed pure red cell aplasia secondary to imatinib.

Patients represented by 441 physicians surveyed from 19 countries, depicted in the patient journey from diagnosis to ensuing treatment with ADT. ADT, androgen.

Clinical courses of patients.

Early lesion analysis to identify potential targets for therapeutic intervention. Early lesion analysis to identify potential targets for therapeutic intervention.

Illustration of common sites of pelvic relapse post-radical cystectomy in patients with ≥pT3 tumours, 9 18 stratified by margins status - (L) positive.

Distribution of TMB and neoantigen load across tumour types.

Mean change from baseline in symptom scales and single-item assessments after 6 weeks of alectinib treatment according to (A) the QLQ-C30 and (B) the QLQ-LC13.

Awareness of respondents about the availability or development of specialised services for AYA where adult and paediatric cancer specialists work together.

Programmed cell death ligand-1 (PD-L1) immunohistochemistry for pulmonary adenocarcinoma tissues. Programmed cell death ligand-1 (PD-L1) immunohistochemistry.

PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.

Tumour types of patients whose cancers harboured actionable molecular alterations in our series. ACUP, adenocarcinoma with unknown primary. Other: appendix.

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Gender representation of board members in all international societies (reference year: 2016). Gender representation of board members in all international.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Application of 5-aminolevulinic acid (5-ALA) induced fluorescence during resection of a brain metastasis. Application of 5-aminolevulinic acid (5-ALA)

(A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus those treated with mono chemotherapy (controls).

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Gender representation in all international congresses (reference year 2016). Gender representation in all international congresses (reference year 2016).

Concentration-time profiles of repeated weekly infusions of (A) 720 mg and (B) 990 mg tomuzotuximab measured in individual patients before and at the end.

Proportion of continuous, intermittent, and limited (

Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.

(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.

On the left, Euler-Venn diagram of point mutations detected by lbNGS and ttNGS on matched genes from the same patients; on the right, the percentage of.

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Three-year DFS rates of T x N subsets of the ACTS-CC trial and IDEA study.19 Annotation: definitions of DFS in ACTS-CC and IDEA were different. Three-year.

Immunochemical staining for HMBG3 in normal cervix, CIN III and invasive carcinomas and could show absent staining in normal cervix (A), absent to weak.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Overview of important signalling pathways in angiogenesis and antiangiogenic agents. Overview of important signalling pathways in angiogenesis and antiangiogenic.

Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Kaplan-Meier plots of (A) time to first improvement and (B) time to first deterioration in pain in the chest, cough and dyspnoea, according to the 13-Item Quality.

Heterogeneity in the natural history of triple negative breast cancer.

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Clinical characteristics at diagnosis of brain metastases.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

(A) Survival curves according to clinical response.

Progesterone receptor (PR)A and PRB isoform receptor domains and post-translational modifications. Progesterone receptor (PR)A and PRB isoform receptor.

Consort diagram of the study depicting the process of patients’ selection. Consort diagram of the study depicting the process of patients’ selection. A.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

(A) Distribution of dMMR proteins in the entire cohort and per tumour type. (A) Distribution of dMMR proteins in the entire cohort and per tumour type.

Prescribers’ responses rating their level of comfort on a scale of 1–5

Prescribers’ responses rating their level of knowledge/understanding on a scale of 1–5. Prescribers’ responses rating their level of knowledge/understanding.

Meta-analysis of the effect of gender in the overall survival, comparing HRs and 95% CI obtained from multivariate analysis in hospital databases. Meta-analysis.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Progesterone receptor nuclear morphology patterns in breast cancer. Progesterone receptor nuclear morphology patterns in breast cancer. (A) Diffuse pattern: homogeneous and diffuse fine granular distribution in the nuclei of tumour cells (×100). (B) Diffuse pattern: homogeneous and diffuse fine granular distribution in the nuclei of tumour cells (×40). (C) Aggregated pattern: heterogeneous distribution of moderate and large spots in the nuclei of tumour cells (×100). (D) Aggregated pattern: heterogeneous distribution of moderate and large spots in the nuclei of tumour cells (×40). Jacques Bonneterre et al. ESMO Open 2016;1:e000072 Copyright © European Society for Medical Oncology. All rights reserved.